

Acquisitions

(January 1st, - January 31st, 2012)

Medical Device/Diagnostics

1)	Avacta , a UK healthcare technology company hopes to obtain \$7.7 million to acquire AptuScan , maker of the Scannin scaffold that offers an alternative to antibodies used in affinity reagents. The company specializes in detection and analysis tools and will also use the proceeds to meet its long-term goals such as tailoring the AptuScan tool to the diagnostic market.
	Clinica (subscription required), 12/30/11
2)	Cutera Inc. , a Brisbane-based company that makes laser machines for vascular problems, hair removal and other cosmetic procedures is acquiring Iridex Corp. "aesthetics" portion of its business, which develops laser-based systems to treat cosmetic blood vessel problems such as leg veins and birthmarks for \$5.1 million. Adding Iridex's technology will allow Cutera to offer a wider range of vascular treatments at multiple price points, Cutera CEO Kevin Connors said in a statement.
	Silicon Valley / San Jose Business Journal, 1/3/12
3)	AAI Pharma Services Corp. , a portfolio company of Water Street Healthcare Partners, has acquired Celsis Analytical Services , a provider of material testing services for the pharma, biotech, and manufacturing markets, from Celsis International Ltd. No financial terms.
	Fortune, 1/4/12
4)	Brooks Automation Inc. , a Chelmsford, MA-based company is acquiring a cell imaging system from Cyntellect Inc. , a San Diego-based company for approximately \$9.2 million. Cyntellect's Celigo cell cytometer is already being used by "many of the top" pharmaceutical, biotechnology and academic institutions around the globe, according to a release by Brooks.
	MassHighTech, 1/4/12
5)	W.M. Barr acquired Microban , a Huntersville, N.C.-based maker of branded antimicrobial ingredients, from The Valence Group, a portfolio company of TA Associates. No financial terms were disclosed.
	Fortune, 1/5/12
6)	Clorox , an Oakland-based company bought HealthLink Inc. , of Jacksonville, Fla., and Aplicare Inc. of Meriden, Conn., for approximately \$80-\$90 million. HealthLink makes antimicrobial hand soap and other products used in medical offices and healthcare facilities. It also makes medical lamps and tests used to detect growth of spores in sterilized liquids. Aplicare makes products to prevent skin infections during surgery or injections.
	San Francisco Business Times, 1/5/12
7)	Quest Diagnostics Incorporated , a provider of diagnostic testing, information and

	services acquired S.E.D. Medical Laboratories , an Albuquerque, New Mexico-based company from Lovelace Health System. Financial terms of the transaction were not disclosed. S.E.D. Medical Laboratories is a medical and federally certified drugs-of-abuse testing laboratory with a staff of 450.
	PeHUB, 1/9/12
8)	RTI International Metals plans to make inroads in the medical device market with its acquisition of Remmele Engineering for \$164.5 million. RTI is looking to benefit from the demand of a growing U.S. medical device contract manufacturing market, which is predicted to hit \$20.3 billion by 2016.
	Reuters, 1/10/12
9)	Vycor Medical subsidiary, NovaVision , a medical device company acquired Sight Science . No financial terms were disclosed. Professor Arash Sahraie has joined NovaVision as its chief scientific officer on a part-time basis from the University of Aberdeen for a minimum of five years. Prof. Sahraie will be responsible for driving NovaVision's scientific effort to develop and validate pioneering technologies in vision rehabilitation for visual field defects resulting from brain injury.
	PeHUB, 1/11/12
10)	CID Capital , a lower-middle market private equity firm acquired Westone Laboratories , a maker of hearing healthcare products and consumer audio products. Terms of the deal were not released.
	PeHUB, 1/12/12
11)	Zimmer Holding Inc. purchased Synvasive Technology , a Reno, Nevada-based company for undisclosed terms. The acquisition will enhance Zimmer's product portfolio through the addition of Synvasive's eLIBRA Dynamic Knee Balancing device and its STABLECUT surgical saw blades.
	Reuters, 1/12/12
12)	Terumo Americas Holding , a U.S. subsidiary of Japan's Terumo Corporation acquired Onset Medical Corporation , a, Irvine, CA medical device company that focuses on developing first-in-class access sheath technology designed for multiple, minimally invasive clinical applications in cardiology and urology. No financial terms disclosed.
	FDAnews.com, 1/17/12
13)	Courtagen Life Sciences Inc. , a Woburn-based company acquired Medicinal Genomics Corp. , another Bay State company, which claims to have sequenced the entire genome of the marijuana plants Cannabis sativa and Cannabis indica. Terms of the acquisition were not disclosed, but Courtagen, a privately held genomics services firm, reported in a news release that the merger "reunites noted genomics pioneers and innovators," brothers Brian McKernan, Brendan McKernan and Kevin McKernan.
	Boston Business Journal, 1/18/12
14)	Cortec Group acquired a majority stake in Cranial Technologies Inc. , a Tempe, Ariz.-

	based maker of medical devices and services for the treatment of positional plagiocephaly in infants. No financial terms were disclosed.
	Fortune, 1/20/12
15)	Roche Diagnostics made a hostile bid to acquire all outstanding shares of San Diego's llumina for \$44.50 per share in cash, or roughly \$5.7 billion. Through the deal, Roche would pick up technology to read genetic makeup of tumors, boosting the potential for targeted personalized medicine in this area, as <i>Bloomberg</i> notes.
	FierceMedicalDevice, 1/25/12
16)	Simbionix , headquarters in Cleveland and Israel, hopes to extend its client base to orthopedic surgeons purchased the Arthro VR line of surgical simulators from GMV , a Spanish company. The devices use a combination of 3D images, fiberglass limb replicas, and haptic sensation to help train physicians in arthroscopic surgery.
	MedCityNews, 1/25/12
17)	AngioDynamics , an Albany, N.Y.-based medical device maker will acquire Navilyst Medical , a privately held Marlborough maker of medical devices for vascular access for \$372 million. The acquisition will significantly expand AngioDynamics' scale, doubling its share of the vascular access market and building critical mass in the peripheral vascular market, according to a press release.
	Boston Business Journal, 1/31/12

Pharma/Biotech

1)	Accelrys , a San Diego-based drug manufacturer is paying \$35 million in cash to acquire VelQuest , a provider of software that enables drugmakers to manage quality-assurance (QA) and quality-control (QA) tasks in a paperless format. Accelrys CEO Max Carnecchia said in a statement: "With the acquisition of VelQuest, Accelrys continues to execute on its strategy of providing a broad, flexible solution set for customers that depend on scientific innovation to bring new products from lab to market more quickly and efficiently."
	FiercePharma, 1/3/12
2)	Cornerstone Therapeutics acquired Cardiokine Inc. , a Philadelphia specialty pharmaceutical company that focused on developing new therapies for heart conditions. The deal includes an upfront payment of \$1 million and contingency payments of more than \$147 million, minus any outstanding liabilities. Cardiokine completed a series of phase-III clinical trials for its lead compound, Lixivaptan, an experimental treatment for a metabolic condition called hyponatremia that occurs when there is not enough sodium in the blood.
	Philadelphia Business Journal, 1/5/12
3)	Bristol-Myers Squibb agreed to acquire Inhibitex Inc. , a maker of hepatitis C drugs, for approximately \$2.5 billion, or \$26 per share (163% premium of the closing price that day). Significant Inhibitex shareholders include New Enterprise Associates (8.8 million shares) and OrbiMed Advisors (2.8 million shares).

	Fortune, 1/9/12
4)	Sigma-Aldrich Corp. , a St. Louis-based life-science and specialty chemical company agreed to acquire BioReliance Holdings Inc. , a Rockville, Md-based biopharmaceutical testing company from Avista Capital Partners for \$350 million in cash. BioReliance Holdings provides biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science companies.
	St. Louis Business Journal, 1/9/12
5)	Covis Pharma Sàrl , a Switzerland- based specialty pharmaceutical company owned by affiliates of Cerberus Capital Management has reached an agreement with GlaxoSmithKline to acquire full commercial rights for Fortaz® (ceftazidime), Zinacef® (cefuroxime), Lanoxin® (digoxin), Parnate® (tranlycypromine sulfate), and Zantac® Injection (ranitidine hydrochloride) in the US and Puerto Rico.
	PeHUB, 1/9/12
6)	Watson Pharmaceuticals expanded its reach in Asia-Pacific by acquiring Strides Arcolab's Australia-based generics business, Ascent Pharmahealth for \$392 million. The buyout not only gives Watson a major presence in Australia, where it becomes the fifth-largest copycat drugmaker, but also No. 1 in Singapore and brings a web of commercial operations in Hong Kong, Vietnam, Malaysia and Thailand.
	FiercePharma, 1/24/12
7)	Opko Health , Miami-based drug development and sales company agreed to acquire a Chilean pharmaceutical company for \$4 million in cash. Opko would buy ALS Distribuidra Limitada from current owners Inversiones SVJV Limitada, Inversiones BS Limitada, and Inversiones PYTT Limitada.
	FDAnews.com, 1/25/12
8)	Celgene Corp. , agreed to acquire Avila Therapeutics Inc. , a Waltham, Mass.–based developer of targeted covalent drugs that treat diseases through protein silencing. The deal is valued at \$350 million in cash, plus up to another \$195 million in earn-outs. Avila shareholders include Abingworth, Advent Venture Partners, Atlas Venture, Novartis Venture Funds, and Polaris Venture Partners. In less than five years Avila Therapeutics gained a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of development.
	Fortune/FierceBiotech, 1/26/12
9)	Amgen Inc. agreed to buy Micromet Inc. for \$1.16 billion to help boost its oncology drug pipeline, Bloomberg reports. Amgen will pay \$11 per share for Micromet, which represents a premium of 33 percent over the company's closing price that day. Micromet was founded in Germany and is based in Rockville, Md. The company is developing an experimental drug, called blinatumomab, which is in mid-stage testing for leukemia.
	San Francisco Business Times, 1/26/12